Default company panoramic image
Logo

Vilya Development, Inc.

Vilya Development's formulation based drug delivery platform has the potential to fundamentally change the treatment of respiratory diseases

  • Stage Product In Development
  • Industry Other
  • Location Napa, CA, USA
  • Currency USD
  • Founded December 2009
  • Employees 3

Company Summary

Vilya Development is a specialty pharmaceutical company focused on the development of novel respiratory products utilizing our proprietary drug deliver platform, which allows for the development of new products with the benefits of new molecular entities at significantly reduced cost and risk. These benefits include:
-Multiple device options
-New IP
-Multiple product opportunities
-Targeted delivery
-Extended release
-Improved safety profi

Team

  • Default avatar
    Robert A Zwolinski
    President

    Rob has18 years of Operations and Quality experience in the development and commercialization of novel pharmaceuticals and drug delivery systems, most recently as Director of Operations at Aradigm, where he was responsible for clinical manufacturing, engineering, and validation for Pulmaquin, the AERx Platform, and DosePro (prior to spin off to Zogenix). Rob has an MBA from the Wharton School and a BS in Biology from the University of Illinois.

  • Default avatar
    Jerry Okikawa
    Head of Operations

    Mr. Okikawa has over 30 years of experience designing and executing a variety of clinical and pre-clinical studies, including significant experience managing global pulmonary clinical studies for the US and European markets. He has held technical and managerial positions at Children’s Hospital Oakland, Nellcor, Aradigm, and MAP Phamaceuticals. Jerry has a BS in Biology from UC Davis, an MBA from St. Mary’s and is a Respiratory Therapist.

  • Default avatar
    Thomas K Garver
    Head of Commercial Affairs

    Mr. Garver has over 40 years of experience in the health care industry including positions with Ciba Pharmaceuticals (Novartis) Bristol Myers Squibb, and Fissons. Tom is one of two active founders of Map Pharmaceuticals where he served as VP Commercial Development. Tom serves on the Boards of Urac Pharma Inc. and Cytologics Inc. He has an AB degree from Drew University in Economics and an MBA from Columbia University.

Advisors

  • Default avatar
    Matthew J. Kim
    Lawyer
    Unconfirmed
    Default avatar
    Victor Crowe
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Robert Zwolinski
    Unconfirmed
    Default avatar
    Jerry Okikawa
    Unconfirmed
    Default avatar
    Thomas Garver
    Unconfirmed